Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.
about
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaWaldenstrom's macroglobulinemia: Recent advances in biology and therapyWaldenström macroglobulinemia: my way.Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusFludarabine in Waldenstrom's macroglobulinemia.Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.How to manage Waldenstrom's macroglobulinemia.Risk stratification in Waldenström macroglobulinemia.Waldenström macroglobulinaemia: the key questions.Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse modelsCurrent and future therapeutic approach for Waldenström's macroglobulinemia.Waldenström Macroglobulinemia: Review of Pathogenesis and Management.Association of β2-microglobulin with the prognosis of non-Hodgkin's lymphoma: a meta analysis.What's new in Waldenström macroglobulinemia.No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years
P2860
Q28237372-B60E98A9-C1CF-4136-A9E1-3C85F8732E2CQ28269017-D4E48E20-3D79-4759-A45E-B5347AF6A204Q33402669-257C5852-04E2-4684-8830-1A20549020C8Q33436642-46C92193-084C-4548-B391-CFE84BF8049DQ34106817-DAB36073-EE70-4AE5-A711-877FABE6ED74Q34351916-652B7A36-A88C-4C76-BF2B-0D497A362F51Q36542990-8105985B-AF9C-4B7A-BA84-EDEB66D03593Q36764811-F1C186CC-A8D5-44E1-9DC0-A7964D3A6D3CQ37999886-0E6EB88C-F326-45EF-B447-6C0CDACDD514Q38104808-EEB112CA-D42A-438C-8163-28BA2A16C6B7Q38150849-0D280BA3-A220-461E-B349-7EE06F594FB0Q38206820-C2B6B477-DED9-4E3E-A712-56EC3A65EBBBQ39214071-D311615E-5071-4EBB-AAE4-3689F110F0DEQ41045903-94EDACF4-FD2E-4B53-BFB2-87857C56883CQ42905789-427187C3-D0B9-46B9-9B39-79021BEE53CFQ57904574-3A67B56C-217D-4F74-9048-EDA31EBBCBDD
P2860
Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Long-term survival in Waldenst ...... irected intergroup trial S9003
@nl
Long-term survival in Waldenst ...... rected intergroup trial S9003.
@ast
Long-term survival in Waldenst ...... rected intergroup trial S9003.
@en
type
label
Long-term survival in Waldenst ...... irected intergroup trial S9003
@nl
Long-term survival in Waldenst ...... rected intergroup trial S9003.
@ast
Long-term survival in Waldenst ...... rected intergroup trial S9003.
@en
prefLabel
Long-term survival in Waldenst ...... irected intergroup trial S9003
@nl
Long-term survival in Waldenst ...... rected intergroup trial S9003.
@ast
Long-term survival in Waldenst ...... rected intergroup trial S9003.
@en
P2093
P2860
P50
P1433
P1476
Long-term survival in Waldenst ...... rected intergroup trial S9003.
@en
P2093
Jackie Szymonifka
John Crowley
Madhav V Dhodapkar
Saul Rivkin
P2860
P304
P356
10.1182/BLOOD-2008-07-172080
P407
P577
2008-10-17T00:00:00Z